Secondary malignant neoplasms after bone and soft tissue sarcomas in children, adolescents, and young adults.
adolescent
child
sarcomas
secondary malignant neoplasms
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
01 05 2022
01 05 2022
Historique:
revised:
05
12
2021
received:
29
07
2021
accepted:
15
12
2021
pubmed:
24
2
2022
medline:
13
4
2022
entrez:
23
2
2022
Statut:
ppublish
Résumé
Increased survival in young sarcoma patients comes along with a higher incidence of second malignant neoplasms (SMNs). The incidence, latency, histiotype, and outcome of these patients were analyzed because this information is essential to design evidence-based long-term follow-up care programs for young sarcoma survivors. Patients entered on clinical trials or registered in registries with a primary sarcoma in 1 of the cooperative sarcoma study groups in the framework of the Society for Pediatric Oncology and Hematology (GPOH) were screened for SMNs. Descriptive analysis, the Kaplan-Meier method, the Gray model, the Fine-Gray model, and the Cox regression model were used for the statistical analyses. A total of 159 out of 7079 (2.2%) patients were registered with a SMN. Among them, 104 solid SMNs (65%) and 56 hematologic SMNs (35%) occurred. Median latency from first diagnosis of sarcoma to the diagnosis of SMN was 6.8 years (range, 0-26.7 years). Cumulative incidence of SMN was 8.8% after 30 years. Five-year-survival was 67.1% (95% confidence interval [CI], 66.0-68.2) for the 7079 patients and it was 45.1% (95% CI, 36.2-53.6) after the diagnosis of a SMN (subcohort of n = 159 patients). There is a remarkable high cumulative incidence of SMNs after bone and soft tissue sarcomas in children, adolescents, and young adults. Therefore, effective transition as well as risk adapted long-term follow-up care programs should be developed and offered to young sarcoma survivors. Bone sarcomas and soft tissue tumors are rare tumors in children, adolescents, and young adults. The treatment varies, but may comprise chemotherapy, surgery, and/or radiotherapy. Developing a subsequent malignant tumor is a long-term risk for the patients. To better characterize this risk, we analyzed the data of 7079 patients (up to 21 years old) with bone sarcomas or soft tissue tumors. Our findings provide a basis to counsel young sarcoma survivors on their individual risk of subsequent malignant tumors. Moreover, these data can help to establish recommendations for aftercare in young sarcoma survivors.
Sections du résumé
BACKGROUND
Increased survival in young sarcoma patients comes along with a higher incidence of second malignant neoplasms (SMNs). The incidence, latency, histiotype, and outcome of these patients were analyzed because this information is essential to design evidence-based long-term follow-up care programs for young sarcoma survivors.
METHODS
Patients entered on clinical trials or registered in registries with a primary sarcoma in 1 of the cooperative sarcoma study groups in the framework of the Society for Pediatric Oncology and Hematology (GPOH) were screened for SMNs. Descriptive analysis, the Kaplan-Meier method, the Gray model, the Fine-Gray model, and the Cox regression model were used for the statistical analyses.
RESULTS
A total of 159 out of 7079 (2.2%) patients were registered with a SMN. Among them, 104 solid SMNs (65%) and 56 hematologic SMNs (35%) occurred. Median latency from first diagnosis of sarcoma to the diagnosis of SMN was 6.8 years (range, 0-26.7 years). Cumulative incidence of SMN was 8.8% after 30 years. Five-year-survival was 67.1% (95% confidence interval [CI], 66.0-68.2) for the 7079 patients and it was 45.1% (95% CI, 36.2-53.6) after the diagnosis of a SMN (subcohort of n = 159 patients).
CONCLUSIONS
There is a remarkable high cumulative incidence of SMNs after bone and soft tissue sarcomas in children, adolescents, and young adults. Therefore, effective transition as well as risk adapted long-term follow-up care programs should be developed and offered to young sarcoma survivors.
LAY SUMMARY
Bone sarcomas and soft tissue tumors are rare tumors in children, adolescents, and young adults. The treatment varies, but may comprise chemotherapy, surgery, and/or radiotherapy. Developing a subsequent malignant tumor is a long-term risk for the patients. To better characterize this risk, we analyzed the data of 7079 patients (up to 21 years old) with bone sarcomas or soft tissue tumors. Our findings provide a basis to counsel young sarcoma survivors on their individual risk of subsequent malignant tumors. Moreover, these data can help to establish recommendations for aftercare in young sarcoma survivors.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1787-1800Informations de copyright
© 2022 American Cancer Society.
Références
Kaatsch P, Debling D, Blettner M, Spix C. Second malignant neoplasms after childhood cancer in Germany-results from the long-term follow-up of the German Childhood Cancer Registry. Strahlenther Onkol 2009;185(suppl 2):8-10.
Ries LAG, Smith MA, Gurney JG, et al, eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. National Institutes of Health; 1999. NIH publication 99-4649.
Erdmann F, Kaatsch P, Grabow D, Spix C. German Childhood Cancer Registry-Annual Report 2019 (1980-2018). Institute of Medical Biostatistics, Epidemiology, and Informatics; 2020.
Kaatsch P, Grabow D, Spix C. German Childhood Cancer Registry-Annual Report 2018 (1980-2017). Institute of Medical Biostatistics, Epidemiology, and Informatics; 2019.
SIOP Europe. The SIOPE Strategic Plan: A European Cancer Plan for Children and Adolescents. SIOP Europe; 2015.
Bright CJ, Reulen RC, Winter DL, et al. Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study. Lancet Oncol. 2019;20:531-545.
Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol. 2009;27:2328-2338.
Pinto N, Hawkins DS. Second malignant neoplasms in rhabdomyosarcoma: victims of our own success or an underlying genetic predisposition syndrome? Pediatr Blood Cancer. 2016;63:189-190.
Caruso J, Shulman DS, DuBois SG. Second malignancies in patients treated for Ewing sarcoma: A systematic review. Pediatr Blood Cancer. 2019;66:e27938.
Bhakta N, Liu Q, Ness KK, et al. The cumulative burden of surviving childhood cancer: an initial report from the St Jude Lifetime Cohort Study (SJLIFE). Lancet. 2017;390:2569-2582.
Pedersen C, Rechnitzer C, Andersen EAW, et al. Somatic disease in survivors of childhood malignant bone tumors in the Nordic countries. Cancers (Basel). 2021;13(18).
Frobisher C, Glaser A, Levitt GA, et al. Risk stratification of childhood cancer survivors necessary for evidence-based clinical long-term follow-up. Br J Cancer. 2017;117:1723-1731.
Friedman DL, Whitton J, Leisenring W, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2010;102:1083-1095.
Mertens AC, Liu Q, Neglia JP, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2008;100:1368-1379.
Meadows AT, Friedman DL, Neglia JP, et al. Second neoplasms in survivors of childhood cancer: findings from the Childhood Cancer Survivor Study cohort. J Clin Oncol. 2009;27:2356-2362.
Hudson MM, Mulrooney DA, Bowers DC, et al. High-risk populations identified in Childhood Cancer Survivor Study investigations: implications for risk-based surveillance. J Clin Oncol. 2009;27:2405-2414.
Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: Childhood Cancer Survivor Study. J Natl Cancer Inst. 2001;93:618-629.
Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48:5358-5362.
Turcotte LM, Neglia JP, Reulen RC, et al. Risk, risk factors, and surveillance of subsequent malignant neoplasms in survivors of childhood cancer: a review. J Clin Oncol. 2018;36:2145-2152.
Teepen JC, van Leeuwen FE, Tissing WJ, et al. Long-term risk of subsequent malignant neoplasms after treatment of childhood cancer in the DCOG LATER study cohort: role of chemotherapy. J Clin Oncol. 2017;35:2288-2298.
Sultan I, Rihani R, Hazin R, Rodriguez-Galindo C. Second malignancies in patients with Ewing sarcoma family of tumors: a population-based study. Acta Oncol. 2010;49:237-244.
Li H, Sisoudiya SD, Martin-Giacalone BA, et al. Germline cancer predisposition variants in pediatric rhabdomyosarcoma: a report from the Children's Oncology Group. J Natl Cancer Inst. 2021;113:875-883.
Kratz CP, Jongmans MC, Cave H, et al. Predisposition to cancer in children and adolescents. Lancet Child Adolesc Health. 2021;5:142-154.
Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006;355:1572-1582.
Hudson MM, Ness KK, Gurney JG, et al. Clinical ascertainment of health outcomes among adults treated for childhood cancer. JAMA. 2013;309:2371-2381.
Record EO, Meacham LR. Survivor care for pediatric cancer survivors: a continuously evolving discipline. Curr Opin Oncol. 2015;27:291-296.
Cooperative Weichteilsarkom Studiengruppe (CWS). CWS-Guidance for Risk Adapted Treatment of Soft Tissue Sarcoma and Soft Tissue Tumours in Children, Adolescents, and Young Adults. Version 1.6.1. Gesellschaft für Pädiatrische Onkologie und Hämatologie; 2014.
Marina NM, Liu Q, Donaldson SS, et al. Longitudinal follow-up of adult survivors of Ewing sarcoma: a report from the Childhood Cancer Survivor Study. Cancer. 2017;123:2551-2560.
Lee JS, DuBois SG, Coccia PF, Bleyer A, Olin RL, Goldsby RE. Increased risk of second malignant neoplasms in adolescents and young adults with cancer. Cancer. 2016;122:116-123.
Robison LL. Treatment-associated subsequent neoplasms among long-term survivors of childhood cancer: the experience of the Childhood Cancer Survivor Study. Pediatr Radiol. 2009;39(suppl 1):S32-S37.
Archer NM, Amorim RP, Naves R, et al. An increased risk of second malignant neoplasms after rhabdomyosarcoma: population-based evidence for a cancer predisposition syndrome? Pediatr Blood Cancer. 2016;63:196-201.
Dantonello TM, Int-Veen C, Harms D, et al. Cooperative trial CWS-91 for localized soft tissue sarcoma in children, adolescents, and young adults. J Clin Oncol. 2009;27:1446-1455.
Henderson TO, Moskowitz CS, Chou JF, et al. Breast cancer risk in childhood cancer survivors without a history of chest radiotherapy: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2016;34:910-918.
Oeffinger KC, Bhatia S. Second primary cancers in survivors of childhood cancer. Lancet. 2009;374:1484-1485.
Chao C, Bhatia S, Xu L, et al. Incidence, risk factors, and mortality associated with second malignant neoplasms among survivors of adolescent and young adult cancer. JAMA Netw Open. 2019;2:e195536.
Lupo PJ, Brown AL, Hettmer S. Second malignancy risk among pediatric, adolescent, and young adult survivors of fusion-positive and fusion-negative sarcomas: results from the SEER database, 1992 through 2012. Cancer. 2016;122:3492-3500.
Sanford NN, Martin AM, Brunner AM, et al. Secondary acute leukemia in sarcoma patients: a population-based study. Int J Radiat Oncol Biol Phys. 2018;100:687-694.
Schiffman JD, Wright J. Ewing's sarcoma and second malignancies. Sarcoma. 2011;2011:736841.
Turcotte LM, Liu Q, Yasui Y, et al. Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer, 1970-2015. JAMA. 2017;317:814-824.
Henderson TO, Rajaraman P, Stovall M, et al. Risk factors associated with secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. Int J Radiat Oncol Biol Phys. 2012;84:224-230.
Berrington de Gonzalez A, Kutsenko A, Rajaraman P. Sarcoma risk after radiation exposure. Clin Sarcoma Res. 2012;2:18.
Wang W, Ollila HM, Whittemore AS, et al. Genetic variants in the HLA class II region associated with risk of cutaneous squamous cell carcinoma. Cancer Immunol Immunother. 2018;67:1123-1133.
Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol. 2005;23:276-292.
Asdahl PH, Winther JF, Bonnesen TG, et al. The Adult Life After Childhood Cancer in Scandinavia (ALiCCS) study: design and characteristics. Pediatr Blood Cancer. 2015;62:2204-2210.
Scholz-Kreisel P, Kaatsch P, Spix C, et al. Second malignancies following childhood cancer treatment in Germany From 1980 to 2014. Dtsch Arztebl Intl. 2018;115:385-392.
Hawkins MM, Wilson LM, Stovall MA, et al. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukemia after childhood cancer. BMJ. 1992;304:951-958.
Turcotte LM, Liu Q, Yasui Y, et al. Chemotherapy and risk of subsequent malignant neoplasms in the Childhood Cancer Survivor Study Cohort. J Clin Oncol. 2019;37:3310-3319.
Tiruneh T, Enawgaw B, Shiferaw E. Genetic pathway in the pathogenesis of therapy-related myeloid neoplasms: a literature review. Oncol Ther. 2020;8:45-57.
Turcotte LM, Whitton JA, Friedman DL, et al. Risk of subsequent neoplasms during the fifth and sixth decades of life in the Childhood Cancer Survivor Study Cohort. J Clin Oncol. 2015;33:3568-3575.
Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol. 1992;19:47-84.
Brown CA, Youlden DR, Aitken JF, Moore AS. Therapy-related acute myeloid leukemia following treatment for cancer in childhood: a population-based registry study. Pediatr Blood Cancer. 2018;65:e27410.
Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer. 2002;2:124-132.
Teepen JC, Kremer LC, van der Heiden-van der Loo M, et al. Clinical characteristics and survival patterns of subsequent sarcoma, breast cancer, and melanoma after childhood cancer in the DCOG-LATER cohort. Cancer Causes Control. 2019;30:909-922.
Mulder RL, Hudson MM, Bhatia S, et al. Updated breast cancer surveillance recommendations for female survivors of childhood, adolescent, and young adult cancer from the International Guideline Harmonization Group. J Clin Oncol. 2020;38:4194-4207.
Morton LM, Onel K, Curtis RE, Hungate EA, Armstrong GT. The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults. Am Soc Clin Oncol Educ Book. 2014:e57-67.
Oeffinger KC, Mertens AC, Hudson MM, et al. Health care of young adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Fam Med. 2004;2:61-70.
Grabow D, Spix C, Blettner M, Kaatsch P. Strategy for long-term surveillance at the German Childhood Cancer Registry - an update. Klin Padiatr. 2011;223:159-164.
Byrne J, Alessi D, Allodji RS, et al. The PanCareSurFup Consortium: research and guidelines to improve lives for survivors of childhood cancer. Eur J Cancer. 2018;103:238-248.